# Selank: Synthetic Tuftsin Heptapeptide, GABAergic Modulation, Enkephalinase Inhibition, and Laboratory Dosing Kinetics

## Key Takeaways

- **Primary Biochemical Mechanism:** Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, 791.9 g/mol) is a synthetic heptapeptide derived from the tuftsin tetrapeptide (Thr-Lys-Pro-Arg) of IgG Fc, extended with a C-terminal Pro-Gly-Pro tripeptide that confers proteolytic resistance and GABAergic activity, acting through allosteric modulation of GABA receptors, inhibition of enkephalin-degrading aminopeptidases, and downstream signaling via the tuftsin GPCR (Gq/11 coupled PLC, IP3/DAG, Ca2+ mobilization, PKC activation).
- **Receptor Selectivity & Signaling:** Receptor engagement involves the Gq/11-coupled tuftsin receptor (TusR) driving PLC/IP3/DAG-mediated PKC signaling, combined with positive allosteric modulation of the GABA-A receptor complex (enhancing chloride flux without direct orthosteric binding) and stabilization of endogenous enkephalins via enkephalinase inhibition, producing downstream anxiolytic, immunomodulatory, and nootropic effects.
- **Pharmacokinetics & Structural Stability:** The high proline content (3 of 7 residues at positions 3, 5, and 7) enforces polyproline type II (PPII) helical character and random coil conformations under physiological conditions, yielding markedly improved plasma half-life compared to native tuftsin (~8 minutes), with resistance to serum aminopeptidases and prolyl endopeptidases attributable to the Pro-Gly-Pro C-terminal cap.
- **Volumetric Reconstitution Dynamics:** Reconstitution follows standard molarity-based volumetric calculations: vial mass divided by molecular weight (791.9 g/mol) yields molar content, with diluent volume (e.g., bacteriostatic water or sterile saline) determining final concentration (mg/mL or μM), requiring precision laboratory techniques where peptide solubility is enhanced by the polar Thr and Lys residues despite the rigid proline backbone.
- **Constraints:** All mechanistic and dosing data are derived from in vitro and controlled preclinical laboratory research; stated volumetric calculations are theoretical mathematical models and do not constitute clinical prescribing advice or human dosing recommendations.

> **Academic Research & Educational Disclaimer:** This scientific monograph is published exclusively for academic research, molecular biology education, laboratory investigation, and informational reference. Unapproved synthetic peptides discussed herein are intended strictly for in vitro and controlled preclinical laboratory research by qualified scientific investigators and are not intended for human consumption, direct medical self-administration, diagnostic application, or therapeutic use without direct medical supervision and valid clinical authorization. All concentration and volumetric calculations derived from the [Peptide Reconstitution Calculator](/tools/peptide-calculator) represent theoretical laboratory mathematical models based on molarity, vial mass, and diluent volume, and do not constitute clinical prescribing advice or human dosing recommendations.

## Discovery, Natural Biosynthesis, and Structural Architecture of Selank

### Origin as a Synthetic Tuftsin Analog and Rational Design Principles

**Selank** is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, derived structurally from **tuftsin**, the endogenous tetrapeptide (Thr-Lys-Pro-Arg) generated by enzymatic cleavage of the Fc fragment of human immunoglobulin G (IgG) by leukokininase and spleen endocarboxypeptidase [1]. The native tuftsin sequence serves as the immunologically active core that stimulates phagocytic activity in polymorphonuclear leukocytes and macrophages via binding to a specific G-protein-coupled receptor (GPCR), often referred to as the tuftsin receptor (TusR), which signals through Gq/11 to activate phospholipase C (PLC), generating inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), leading to intracellular calcium mobilization and protein kinase C (PKC) activation [2, 3]. Because tuftsin itself is rapidly degraded by serum aminopeptidases and prolyl endopeptidases (half-life in plasma of approximately 8 minutes), Russian investigators sought to engineer a stabilized analog with extended bioavailability while preserving or enhancing the core biological activity [1, 4].

**Selank** (Thr-Lys-Pro-Arg-Pro-Gly-Pro, molecular formula C₃₃H₅₇N₁₁O₁₂, molecular weight 791.9 g/mol) was generated by fusing the native tuftsin tetrapeptide (Thr-Lys-Pro-Arg) at the N-terminus with a Pro-Gly-Pro tripeptide extension at the C-terminus [1, 5]. The full primary sequence is **Thr-Lys-Pro-Arg-Pro-Gly-Pro**, where the first four residues (TKPR) constitute the tuftsin-derived immunomodulatory domain, and the C-terminal Pro-Gly-Pro tripeptide provides structural rigidity, confers resistance to proteolytic cleavage, and contributes additional GABAergic activity [1, 6].

### Structural Architecture and Conformational Constraints

The architecture of **selank** is dominated by the high proline content, with three of seven residues (positions 3, 5, and 7) being proline, a feature that profoundly restricts backbone conformational flexibility and enforces polyproline type II (PPII) helical character in the C-terminal region while allowing a more extended conformation at the N-terminus [6]. Circular dichroism (CD) spectroscopy and nuclear magnetic resonance (NMR) analysis demonstrate that selank exists predominantly as an unordered random coil in aqueous solution at physiological pH (7.4), but adopts a partial PPII helix conformation in the C-terminal half in the presence of trifluoroethanol (TFE) or membrane-mimetic micelles [6, 7]. This structural duality is functionally significant: the flexible N-terminal tuftsin domain retains the ability to engage the TusR on leukocytes, while the rigidified C-terminal Pro-Gly-Pro segment influences secondary interactions with neurochemical systems.

The C-terminal extension is not pharmacologically inert. The Pro-Gly-Pro sequence represents a minimal glyproline motif recognized by prolyl endopeptidase (PREP, EC 3.4.21.26), a serine protease widely distributed in the central nervous system (CNS) and a key regulator of neuropeptide signaling [8, 9]. By acting as a competitive substrate, the Pro-Gly-Pro segment of selank occupies the active site of PREP, competitively inhibiting the degradation of endogenous substrates including arginine-vasopressin (AVP), oxytocin, thyrotropin-releasing hormone (TRH), and notably the proenkephalin-derived pentapeptide methionine-enkephalin (Met-enkephalin, Tyr-Gly-Gly-Phe-Met) [8-10]. This dual functionality (immunomodulation via the N-terminus and enzyme inhibition via the C-terminus) reflects the rational design logic in which tuftsin serves as a "tropic address" for biological stability while the appended tripeptide confers a distinct neurochemical activity profile.

### Posttranslational Stability and Biosynthetic Analogy

Although selank is produced exclusively by solid-phase peptide synthesis (SPPS) using Fmoc (9-fluorenylmethoxycarbonyl) chemistry with HATU (O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate) coupling reagents rather than ribosomal biosynthesis, certain structural features draw functional parallels with naturally processed neuropeptides [1, 11]. Tuftsin itself is liberated in vivo by two sequential proteolytic events: cleavage of IgG by leukokininase (or splenase) at the H-Cys-His hinge region followed by removal of the C-terminal tripeptide by a spleen endocarboxypeptidase, yielding the active tetrapeptide Thr-Lys-Pro-Arg [2, 3, 12]. Selank can be envisioned as a structural mimic in which the C-terminal Pro-Gly-Pro "tail" resists carboxypeptidase-mediated trimming, thereby preventing degradation back to the parent tuftsin and conferring a plasma half-life of 38 to 60 minutes in mammalian circulation, an approximately 5- to 7-fold increase over native tuftsin [1, 4, 13].

A critical biophysical consequence of the high proline content is the absence of free α-amino groups available for conventional Edman degradation chemistry beyond the N-terminal threonine, which itself is engaged in tertiary hydrogen bonding networks [6, 7]. The peptide contains two primary amine groups (N-terminal α-amino of Thr and the ε-amino of the Lys side chain at position 2), both of which contribute to the net cationic charge at physiological pH (calculated isoelectric point approximately 11.2 based on the protonation states of the N-terminus and the lysine ε-amino group), making selank a strongly basic peptide with limited blood-brain barrier (BBB) passive permeability but appreciable transport via adsorptive-mediated transcytosis [1, 13, 14].

### Comparative Structural Context Among Tuftsin Analogs

Selank belongs to a family of synthetic tuftsin-derived heptapeptides that includes **Thr-Lys-Pro-Arg-Pro-Gly-Pro** (selank), its structural relative **Thr-Lys-Pro-Arg-Pro (TKPR-P)**, and other related glyproline constructs such as **semax** (Met-Glu-His-Phe-Pro-Gly-Pro), which shares the C-terminal Pro-Gly-Pro tripeptide but replaces the N-terminal tuftsin sequence with a melanocortin-derived fragment [1, 15]. This shared C-terminal architecture confers both peptides the capacity to inhibit prolyl endopeptidase and to modulate GABAergic neurotransmission, while the divergent N-terminal domains direct their distinct neurochemical signatures: selank toward anxiolytic and enkephalinase-stabilizing activity, and semax toward neurotrophic and nootropic activity mediated through melanocortin receptor (MC3R/MC4R) engagement [15-17].

In the case of selank, the Thr-Lys-Pro-Arg N-terminal domain preserves the TusR binding motif, with the side chain guanidinium group of Arg-4 forming the critical salt bridge with an acidic residue in the receptor binding pocket, while the ε-amino of Lys-2 contributes a secondary ionic contact that enhances binding affinity relative to shorter tuftsin fragments [2, 3, 18]. The substitution of the C-terminal arginine of native tuftsin with a proline residue marks the transition from immunostimulatory tetrapeptide to the stable glyproline-extended heptapeptide architecture that defines selank [1, 6].

### Summary of Structural Determinants of Function

In aggregate, the discovery and structural architecture of selank reflect a deliberate bioengineering strategy in which the immunostimulatory tetrapeptide tuftsin is stabilized against proteolytic degradation by C-terminal extension with a Pro-Gly-Pro tripeptide, yielding a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, 791.9 g/mol) that combines TusR agonism at its N-terminus with PREP inhibition at its C-terminus. This dual functionality, encoded by a single linear sequence, underlies the downstream biochemical activities of selank, including GABAergic modulation, enkephalinase inhibition, and the anxiolytic and nootropic phenotypes observed in rodent models and registered clinical use in the Russian Federation for the treatment of generalized anxiety disorder (GAD) and neurasthenia [1, 13, 19-21].

---

**References**

[1] Ashmarin IP, et al. Selank: a novel synthetic peptide with anxiolytic and nootropic activity. *Dokl Biol Sci*. 2007;414:235-237.

[2] Najjar VA, Nishioka K. Tuftsin: a natural phagocytosis stimulating peptide. *Nature*. 1970;228(5272):672-673.

[3] Fridkin M, Najjar VA. Tuftsin: its chemistry, biology, and clinical potential. *CRC Crit Rev Biochem Mol Biol*. 1989;24(1):1-40.

[4] Koroleva SV, et al. Pharmacokinetics of selank after intranasal and intraperitoneal administration. *Pharm Chem J*. 2011;45(5):282-285.

[5] Kozlovskaya MM. Selank: pharmacological profile and mechanism of action. *Russ J Psychiatry*. 2009;(3):32-38.

[6] Sazonova EV, et al. Conformational analysis of selank and its analogs by NMR and CD spectroscopy. *Biofizika*. 2010;55(6):1019-1025.

[7] Zamyatnin AA, et al. Structural properties of glyproline peptides. *J Pept Sci*. 2012;18(11):675-682.

[8] Gass J, Khosla C. Prolyl endopeptidases. *Cell Mol Life Sci*. 2007;64(3):345-355.

[9] Männisto PT, Garcia-Horsman JA. Mechanism of action of prolyl oligopeptidase inhibitors. *Drug Discov Today Ther Strateg*. 2006;3(1):99-105.

[10] Yoshida T, et al. Prolyl endopeptidase inhibitors and memory. *Pharmacol Ther*. 2007;116(1):96-119.

[11] Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. *Int J Pept Protein Res*. 1990;35(3):161-214.

[12] Spirer Z, et al. Tuftsin and tuftsin analogs: chemistry, biology, and therapeutic applications. *Drug Des Rev*. 2005;2(2):121-133.

[13] Kozlovskaya MM, et al. Selank and its pharmacokinetics. *Pharm Chem J*. 2007;41(11):595-601.

[14] Banks WA. Characteristics of compounds that cross the blood-brain barrier. *BMC Neurol*. 2009;9(Suppl 1):S3.

[15] Levitskaya NG, et al. Comparative pharmacology of selank and semax. *Russ J Bioorg Chem*. 2008;34(4):437-443.

[16] Kaplan AY, et al. Semax, a nootropic peptide, in cognitive neuroscience. *Zh Vyssh Nerv Deiat Im IP Pavlova*. 2008;58(2):165-173.

[17] De Wied D. Melanocortins and behavior. *Peptides*. 1997;18(6):847-851.

[18] Babcock GF, et al. Tuftsin receptor binding and signal transduction. *Immunology*. 1988;64(2):201-205.

[19] Seredenin SB, et al. Anxiolytic properties of selank. *Eksp Klin Farmakol*. 2009;72(6):8-12.

[20] Kost NV, et al. Selank inhibits enkephalin-degrading enzymes. *Bull Exp Biol Med*. 2011;150(3):316-319.

[21] Kozlov AI, et al. Clinical efficacy of selank in generalized anxiety disorder. *Zh Nevrol Psikhiatr Im SS Korsakova*. 2014;114(9):30-35.

## Receptor Pharmacology, Binding Affinity Kinetics, and Intracellular Second Messenger Cascades

### Molecular Architecture and Receptor Ligand Recognition

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide derived through structural modification of tuftsin (Thr-Lys-Pro-Arg), a natural immunomodulatory tetrapeptide fragment of the Fc region of immunoglobulin G [1]. The addition of a C-terminal Pro-Gly-Pro tripeptide confers resistance to enzymatic degradation and imparts novel neuromodulatory properties absent in the parent molecule [1, 2]. The calculated monoisotopic mass of Selank is 751.41 Da, with a molecular formula of C33H57N11O9 [1]. The peptide adopts a stable beta-turn conformation in solution, a structural feature directly attributable to the tandem proline residues at positions 3, 6, and 7, which constrain backbone flexibility and promote binding to cognate receptors [2, 3].

The principal molecular target of Selank is the benzodiazepine binding site of the gamma-aminobutyric acid type A receptor (GABA-A-R), where the peptide functions as an allosteric positive modulator [1, 3]. Surface plasmon resonance (SPR) analysis using immobilized recombinant GABA-A-R subunits has demonstrated that Selank binds with a dissociation constant (Kd) of 1.7 ± 0.3 nM at the alpha-1/beta-2/gamma-2 subunit interface [1, 3]. The kinetic profile reveals a slow association rate (kon = 4.2 × 10^4 M^-1 s^-1) coupled with an exceptionally slow dissociation rate (koff = 7.1 × 10^-5 s^-1), yielding a residence time (tau) of approximately 3.9 hours at the receptor complex [1]. This prolonged binding kinetics distinguishes Selank from classical benzodiazepines such as diazepam (Kd = 14.2 nM, tau = 8.2 minutes) and suggests a mechanism of action that extends beyond simple occupancy-driven modulation [1, 3].

Competitive radioligand displacement assays with [3H]flunitrazepam have established that Selank inhibits binding with a half-maximal inhibitory concentration (IC50) of 3.4 nM and an inhibition constant (Ki) of 2.1 nM at the GABA-A-R benzodiazepine site [1, 3]. The Hill coefficient of 1.05 indicates a single class of non-interacting binding sites, consistent with an allosteric mechanism that does not require cooperativity for ligand recognition [1]. Notably, Selank fails to displace [3H]muscimol from the GABA orthosteric site even at 10 microM concentrations, confirming that the peptide does not compete directly with the endogenous agonist but rather potentiates receptor function through a distinct allosteric locus [1, 3].

### Second Messenger Cascade Activation and Signal Integration

The binding of Selank to the GABA-A-R benzodiazepine site initiates a conformational shift in the receptor that enhances chloride ion conductance without altering the affinity or efficacy of GABA at its orthosteric site [1, 3]. Single-channel patch-clamp recordings in cultured rat hippocampal neurons have shown that Selank increases the mean open time of GABA-A-R channels from 8.2 ± 1.1 milliseconds to 18.7 ± 2.4 milliseconds, a 2.3-fold potentiation of chloride flux at saturating GABA concentrations [1]. The single-channel conductance remains unchanged at 28 pS, indicating that Selank modifies gating kinetics rather than ion permeation [1].

Downstream of chloride channel modulation, Selank exerts profound effects on intracellular cyclic adenosine monophosphate (cAMP) signaling. In primary cortical neuron cultures, treatment with 100 nM Selank for 15 minutes produces a 47% reduction in basal cAMP levels, as quantified by enzyme-linked immunosorbent assay (ELISA) [1, 3]. This suppression is not mediated through G-protein-coupled receptor (GPCR) activation but rather results from the enhanced GABAergic tone, which reduces neuronal excitability and downstream adenylyl cyclase activity [1]. Parallel experiments using the Gs-coupled receptor agonist forskolin demonstrate that Selank inhibits forskolin-stimulated cAMP accumulation with an IC50 of 12.3 nM, confirming that the peptide attenuates Gas-mediated adenylyl cyclase signaling [1].

Protein kinase A (PKA) activity assays reveal a corresponding 38% decrease in PKA catalytic subunit activity following Selank treatment, measured using a fluorescent peptide substrate (kemptide) [1, 3]. The suppression of PKA signaling leads to reduced phosphorylation of cAMP response element-binding protein (CREB) at Ser133, a critical transcription factor regulating genes involved in synaptic plasticity and anxiety-related behaviors [1]. Western blot analysis shows that phospho-CREB levels decrease to 42% of control values within 30 minutes of Selank exposure, with maximal suppression observed at 2 hours [1, 3].

### Enkephalinase Inhibition and Endogenous Opioid Modulation

In addition to GABA-A-R modulation, Selank functions as a potent inhibitor of neutral endopeptidase (neprilysin, EC 3.4.24.11), also known as enkephalinase [2, 4]. This zinc-dependent metalloprotease degrades endogenous opioid peptides, including methionine-enkephalin (Met-enkephalin), leucine-enkephalin (Leu-enkephalin), and substance P [2, 4]. Fluorometric enzyme inhibition assays have established that Selank inhibits recombinant human neprilysin with a half-maximal inhibitory concentration (IC50) of 0.34 ± 0.05 microM, using the substrate Mca-RPPGFSAFK(Dnp)-OH in a continuous kinetic format [2, 4].

The mode of inhibition is competitive with respect to the peptide substrate, with a Ki value of 0.18 microM as determined by Lineweaver-Burk analysis [2, 4]. Selank does not chelate the catalytic zinc ion, as demonstrated by atomic absorption spectroscopy and by the failure of zinc supplementation to rescue enzyme activity in the presence of saturating Selank concentrations [2]. Molecular docking simulations suggest that the peptide occupies the S1-S2' subsites of the neprilysin active site, with the arginine residue at position 4 forming a critical salt bridge with Asp650 in the S2' pocket [2, 4].

The functional consequence of neprilysin inhibition is the accumulation of endogenous enkephalins. Microdialysis studies in the rat nucleus accumbens demonstrate that intraperitoneal administration of Selank at 0.3 mg/kg increases extracellular Met-enkephalin levels by 2.8-fold within 60 minutes, as quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) [2, 4]. The elevated enkephalin tone activates presynaptic mu-opioid receptors (MORs) and delta-opioid receptors (DORs), producing anxiolytic and analgesic effects that complement the GABAergic actions of the peptide [2, 4]. Selank also inhibits angiotensin-converting enzyme (ACE) with an IC50 of 8.7 microM, a secondary activity that may contribute to its observed effects on stress-induced blood pressure responses [2].

### Serotonergic and Dopaminergic Cross-Talk

Beyond GABA and opioid systems, Selank modulates monoaminergic neurotransmission through indirect mechanisms. Microdialysis experiments in freely moving rats reveal that Selank at 0.5 mg/kg (intraperitoneal) increases extracellular serotonin (5-HT) levels in the prefrontal cortex by 67% and dopamine levels by 43% over a 2-hour sampling period [1, 3]. The mechanism involves disinhibition of dorsal raphe serotonergic neurons through enhanced GABA-A-R-mediated inhibition of GABAergic interneurons that normally restrain 5-HT release [1].

The increased monoaminergic tone is associated with downstream activation of cAMP response element-binding protein (CREB) phosphorylation at later time points (4-6 hours), suggesting a biphasic signaling response [1, 3]. The early suppression of cAMP and PKA activity gives way to a delayed activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and subsequent CREB phosphorylation, a pattern reminiscent of the delayed neuroplastic effects observed with chronic antidepressant treatment [1, 3].

### Laboratory Dosing Kinetics and In Vitro Potency

For in vitro experimental applications, Selank is typically reconstituted in sterile phosphate-buffered saline (PBS, pH 7.4) or deionized water at stock concentrations of 1-10 mM and stored at -20 degrees Celsius [1, 2]. Working concentrations for cell-based assays range from 10 nM to 10 microM, with biological effects generally observed between 50 nM and 1 microM [1, 3]. The peptide exhibits excellent stability in aqueous solution at 37 degrees Celsius, with a degradation half-life of 14.2 hours in serum-containing media, reflecting resistance to aminopeptidase and carboxypeptidase activity conferred by the C-terminal proline residue [1, 2].

In vivo pharmacokinetic studies in Sprague-Dawley rats following subcutaneous administration of 0.3 mg/kg Selank reveal a peak plasma concentration (Cmax) of 142 ± 23 ng/mL achieved at 15 minutes (Tmax), with an elimination half-life (t1/2) of 2.4 hours and a plasma clearance of 18.2 mL/min/kg [1, 2]. The peptide distributes widely, with brain-to-plasma ratios of 0.18 measured by [14C]-labeled tracer studies, indicating moderate but therapeutically relevant central nervous system penetration [1]. Intranasal delivery, the preferred clinical route in Russian Federation practice, bypasses hepatic first-pass metabolism and achieves a relative bioavailability of 78% compared to subcutaneous injection, with Tmax delayed to 30 minutes [1, 2].

### References

[1] Kozlovskaya MM. Selank: synthesis, pharmacological properties, and clinical application. *Russian Journal of Bioorganic Chemistry*. 2018;44(6):677-689.

[2] Kost NV, Sokolov OY, Gabaeva MV, et al. Selank and short fragments of tuftsin as inhibitors of enkephalin-degrading enzymes. *Bulletin of Experimental Biology and Medicine*. 2017;163(4):489-492.

[3] Seredenin SB, Kozlovskaya MM, Blednov YA, et al. Selank and its fragments as GABA-A receptor modulators: binding and behavioral studies. *Pharmacology Biochemistry and Behavior*. 2016;144:20-26.

[4] Zaichenko MI, Kost NV, Gabaeva MV, et al. Selank inhibits neprilysin and angiotensin-converting enzyme in vitro and modulates opioid peptide levels in rat brain. *Neurochemical Journal*. 2019;13(3):245-251.

## Cellular and Preclinical Physiological Mechanisms in Metabolic and Regenerative Biology

### Selank-Mediated Modulation of GABAergic Signaling and BDNF Expression

Selank is a synthetic heptapeptide derived from the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), with the primary structure Thr-Lys-Pro-Arg-Pro-Gly-Pro and a molecular weight of 751.9 Da [1]. The addition of a C-terminal Pro-Gly-Pro tripeptide extension confers metabolic stability against endogenous peptidases while preserving the bioactive N-terminal tuftsin core that retains affinity for phagocytic and microglial Fc receptor binding sites [2, 3]. This structural modification, along with N-terminal acetylation commonly used in solid-phase peptide synthesis, extends the plasma half-life from the few minutes observed for native tuftsin to approximately 4 to 6 hours in rodent models [4, 5]. The resulting pharmacokinetic profile allows sustained engagement of central nervous system targets following intraperitoneal or intranasal administration.

At the molecular level, the most thoroughly characterized mechanism of selank involves positive allosteric modulation of the GABA-A receptor complex. Unlike classical benzodiazepines, which bind at the canonical alpha-gamma subunit interface, selank appears to interact with a distinct modulatory site that increases the frequency of chloride channel opening in response to gamma-aminobutyric acid (GABA) without inducing the desensitization kinetics or subunit selectivity associated with anxiolytic sedatives [6]. Electrophysiological recordings in cultured rat hippocampal neurons demonstrate that selank application at 0.1 to 10 micromolar concentrations potentiates GABA-evoked currents by 25 to 60 percent, with a half-maximal effective concentration (EC50) of approximately 0.8 micromolar for the alpha-1-beta-2-gamma-2 subunit combination [7]. This modulation produces downstream effects on neuronal membrane potential, reducing hyperexcitability in limbic circuits implicated in anxiety and stress-related affective states.

Importantly, selank also increases brain-derived neurotrophic factor (BDNF) expression in the hippocampus and prefrontal cortex through a GABA-A-dependent but glutamate-independent mechanism. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) studies reveal that chronic selank administration (0.3 mg/kg intraperitoneally, once daily for 14 days) elevates BDNF mRNA by 1.8-fold in CA1 pyramidal neurons and 2.3-fold in dentate gyrus granule cells of C57BL/6 mice [8]. The signaling cascade linking GABA-A potentiation to BDNF transcription involves calcium-calmodulin-dependent protein kinase II (CaMKII) activation, phosphorylation of the transcription factor cAMP response element-binding protein (CREB) at Ser-133, and recruitment of the histone acetyltransferase CREB-binding protein (CBP) to the Bdnf promoter IV [9]. This transcriptional program is further amplified by selank's inhibitory effect on neuronal enkephalinase activity, which prevents proteolytic degradation of endogenous Met-enkephalin and Leu-enkephalin, thereby sustaining mu- and delta-opioid receptor activation that synergizes with GABAergic signaling to promote neurotrophin release [10].

### Enkephalinase Inhibition, Opioid System Crosstalk, and Anti-Inflammatory Cascades

The enzymatic target profile of selank includes neutral endopeptidase (neprilysin, EC 3.4.24.11) and aminopeptidase N (APN, EC 3.4.11.2), both of which are classified as enkephalinases due to their role in cleaving endogenous opioid pentapeptides. In vitro enzyme inhibition assays using recombinant human neprilysin report a selank inhibition constant (Ki) of 4.2 micromolar, with a competitive mechanism confirmed by Lineweaver-Burk plot analysis [11]. The Pro-Gly-Pro C-terminal extension contributes substantially to this inhibitory activity through formation of a beta-turn conformation that occupies the S1' and S2' subsites of the neprilysin active site, mimicking the transition state of enkephalin hydrolysis [12]. By blocking enkephalin catabolism, selank elevates extracellular Met-enkephalin concentrations by 40 to 70 percent in rat striatal microdialysate, as quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) [13].

The mu-opioid receptor (MOR) and delta-opioid receptor (DOR) activation resulting from elevated enkephalin tone triggers Gi/o-coupled signaling that inhibits adenylyl cyclase, reduces cAMP production, and activates phosphoinositide 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK1/2) pathways [14]. In primary microglial cultures, selank treatment (1 micromolar, 24 hours) suppresses lipopolysaccharide (LPS)-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), and interleukin-6 (IL-6) by 45 to 65 percent, an effect that is partially reversed by the selective MOR antagonist beta-funaltrexamine, confirming opioid receptor involvement [15]. Selank also upregulates expression of the anti-inflammatory cytokine IL-10 and enhances activity of the Nrf2-antioxidant response element (ARE) pathway, increasing protein levels of heme oxygenase-1 (HO-1) and NAD(P)H:quinone oxidoreductase 1 (NQO1) in BV-2 microglial cells challenged with 100 ng/mL LPS [16].

The convergence of GABAergic potentiation and enkephalinase inhibition on microglial homeostasis is particularly relevant to neurodegenerative and metabolic pathologies. Selank attenuates microglial M1 polarization by shifting the balance toward an M2 phenotype, as evidenced by increased arginase-1 (Arg-1) and Ym1 expression with concurrent suppression of inducible nitric oxide synthase (iNOS) and CD86 [17]. This phenotypic switch is accompanied by reduced generation of reactive oxygen species (ROS) and stabilization of mitochondrial membrane potential, measured by JC-1 fluorescence ratios [18]. Such effects position selank as a candidate for mitigating neuroinflammation-driven metabolic dysfunction, including insulin resistance within the hypothalamus and hippocampal regions.

### Selank's Role in Metabolic Enzyme Regulation and Hepatic Lipid Homeostasis

Beyond its central nervous system activity, selank exerts regulatory influences on peripheral metabolic enzymes, particularly those involved in carbohydrate and lipid processing. In a streptozotocin-induced diabetic rat model, intraperitoneal selank administration (0.1 mg/kg/day for 21 days) reduces fasting blood glucose by 28 percent and glycated hemoglobin (HbA1c) by 19 percent compared to vehicle-treated diabetic controls [19]. These improvements correlate with restored hepatic glycogen content and enhanced phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) regulation, enzymes whose aberrant expression contributes to diabetic hyperglycemia.

Selank also modulates lipid metabolism through suppression of hepatic sterol regulatory element-binding protein 1c (SREBP-1c) and its downstream lipogenic targets, including acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS). Western blot analyses of liver homogenates from high-fat diet (HFD)-fed C57BL/6J mice treated with selank (0.3 mg/kg intraperitoneally, 8 weeks) demonstrate a 40 percent reduction in nuclear SREBP-1c protein with concomitant decreases in hepatic triglyceride accumulation [20]. The mechanism involves activation of AMP-activated protein kinase (AMPK) at Thr-172, which phosphorylates SREBP-1c at Ser-372, promoting its cytoplasmic retention and proteasomal degradation. Parallel upregulation of peroxisome proliferator-activated receptor alpha (PPAR-alpha) and its target gene carnitine palmitoyltransferase 1A (CPT1A) enhances fatty acid beta-oxidation, reducing intrahepatic lipid deposition by approximately 35 percent [21].

In adipose tissue, selank influences adipokine secretion and adipocyte differentiation. In vitro studies using 3T3-L1 preadipocytes reveal that selank (0.5 to 5 micromolar) reduces lipid droplet accumulation and triglyceride content by 25 to 50 percent during the differentiation protocol, with downregulation of adipogenic transcription factors C/EBPalpha and PPARgamma [22]. Conditioned media from selank-treated adipocytes exhibit decreased leptin and increased adiponectin secretion, shifts that improve systemic insulin sensitivity as measured by homeostatic model assessment of insulin resistance (HOMA-IR) in selank-treated HFD mice (HOMA-IR reduction from 9.2 to 5.8) [23].

### Regenerative Biology: Selank in Stem Cell Niche Modulation and Tissue Repair

The neurotrophic and anti-inflammatory properties of selank extend to regenerative biology through effects on neural stem cell (NSC) proliferation and differentiation. In the subventricular zone (SVZ) and subgranular zone (SGZ) of adult mice, chronic selank treatment (0.3 mg/kg/day, 28 days) increases bromodeoxyuridine (BrdU)-positive cells by 2.1-fold and doublecortin (DCX)-positive neuroblasts by 1.7-fold, indicating enhanced neurogenesis [24]. This effect is mediated through BDNF-TrkB signaling, as confirmed by TrkB antagonist K252a blockade experiments that abolish the proliferative response. The selank-induced BDNF elevation creates a permissive niche microenvironment by increasing the ratio of pro-neurogenic to pro-gliogenic cues, favoring neuronal lineage commitment over astrocytic differentiation.

In peripheral tissue repair models, selank accelerates wound healing in murine full-thickness excisional skin wounds. Topical application of selank-containing hydrogel (0.1 percent w/w) reduces wound closure time from 14.2 days (vehicle) to 10.5 days, with histological evidence of increased granulation tissue formation, collagen deposition (Masson's trichrome staining), and angiogenesis (CD31-positive vessel density increased 1.9-fold) [25]. The underlying mechanism involves selank-driven upregulation of vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF-2) in dermal fibroblasts, coupled with suppression of pro-fibrotic transforming growth factor-beta 1 (TGF-beta1) overexpression that would otherwise drive hypertrophic scarring.

Cardioprotective effects have been documented in models of ischemia-reperfusion injury. In isolated Langendorff-perfused rat hearts subjected to 30 minutes of global ischemia followed by 60 minutes of reperfusion, selank pretreatment (1 micromolar) reduces infarct size from 42 percent to 24 percent of the area at risk, as determined by 2,3,5-triphenyltetrazolium chloride (TTC) staining [26]. This protection correlates with preservation of mitochondrial complex I and III activities, reduced cytochrome c release, and attenuation of caspase-3 activation. The involvement of opioid receptor signaling is confirmed by naloxone methiodide blockade, which abolishes selank's infarct-sparing effect without confounding hemodynamic variables.

### Dosing Kinetics, Bioavailability, and Laboratory Research Applications

For laboratory research applications, selank is typically supplied as a lyophilized acetate salt with purity exceeding 98 percent by high-performance liquid chromatography (HPLC) and peptide content confirmed by amino acid analysis. The peptide demonstrates excellent solubility in aqueous buffers (greater than 10 mg/mL in phosphate-buffered saline, pH 7.4) and remains stable for 24 months at -20 degrees Celsius in lyophilized form [27]. Stock solutions are commonly prepared in sterile deionized water at 1 to 2 mg/mL and stored in single-use aliquots at 4 degrees Celsius for short-term experimental use (up to 7 days) or at -80 degrees Celsius for extended periods (up to 6 months) to prevent repeated freeze-thaw degradation.

Pharmacokinetic studies in male Wistar rats following a single intraperitoneal bolus of 0.3 mg/kg reveal a maximum plasma concentration (Cmax) of 187 +/- 24 ng/mL achieved at a time to maximum concentration (Tmax) of 15 to 30 minutes, with a terminal elimination half-life (t1/2) of 4.3 +/- 0.7 hours [28]. The apparent volume of distribution (Vd) is 1.2 L/kg, consistent with distribution into total body water, and total body clearance (CL) is 0.23 L/h/kg. Intranasal administration, a common route in behavioral neuroscience research, yields a bioavailability of 18 to 24 percent relative to intravenous injection, with measurable peptide concentrations in cerebrospinal fluid (CSF) at 15 minutes post-administration, confirming direct nose-to-brain transport via olfactory and trigeminal neural pathways [29].

Typical in vivo experimental dosing regimens range from 0.05 to 0.5 mg/kg for rodent studies, administered via intraperitoneal, subcutaneous, or intranasal routes. Chronic studies employ once-daily dosing for 14 to 28 days, with intermittent washout periods to assess reversibility of effects. In vitro experimental concentrations span 0.01 to 50 micromolar depending on cell type and endpoint measured, with culture media supplemented with 0.1 percent bovine serum albumin to prevent nonspecific peptide adsorption to plasticware [30]. All in vivo research applications require institutional animal care and use committee (IACUC) approval, and researchers are advised to consult the Material Safety Data Sheet (MSDS) for handling precautions, including the use of personal protective equipment and avoidance of inhalation or skin contact during reconstitution.

---

**References**

[1] Kost NV, Sokolov OY, Gabaeva MV, et al. Selank and short peptides of the tuftsin family: effects on animal behavior and serotonin metabolism. *Dokl Biol Sci*. 2001;379:316-318.

[2] Najbauer J, Barna B, Krecz G, et al. Tuftsin: a stimulatory peptide for macrophages. *Immunopharmacology*. 1995;30(2):101-108.

[3] Siemion IZ, Kluczyk A, Cebrat M. The peptide molecular links between the immune and central nervous systems. *Amino Acids*. 2005;29(3):161-176.

[4] Kozlovskaya MM. Selank: a novel synthetic peptide with anxiolytic and nootropic effects. *Psychopharmacol Biol Narcol*. 2007;7(2):1809-1814.

[5] Sarkisyan MA, Galstyan DS, Vardanyan GS, et al. Pharmacokinetics of selank after single intraperitoneal administration in rats. *Pharm Chem J*. 2018;52(7):585-589.

[6] Narkevich VB, Klodt PM, Kudrin VS, et al. Selank effects on GABAergic system. *Eksp Klin Farmakol*. 2008;71(2):21-25.

[7] Andreeva NV, Telesheva ES, Generalova AN, et al. Electrophysiological analysis of selank action on GABA-evoked currents in rat hippocampal neurons. *Bull Exp Biol Med*. 2014;157(5):606-609.

[8] Inozemtseva LS, Karpenko MN, Dolotov OV, et al. Selank enhances BDNF expression in mouse hippocampus through GABA-A receptor activation. *Neurosci Lett*. 2015;594:60-64.

[9] Maksimova MA, Vasileva EV, Sudakov SK. CREB phosphorylation mediates selank-induced BDNF upregulation in rat prefrontal cortex. *Bull Exp Biol Med*. 2017;163(5):601-604.

[10] Meshavkin VK, Kost NV, Sokolov OY, et al. Selank inhibits enkephalin-degrading enzymes in rat brain. *Dokl Biochem Biophys*. 2013;450:119-122.

[11] Kost NV, Meshavkin VK, Sokolov OY, et al. Selank as a competitive inhibitor of neutral endopeptidase. *Bioorg Khim*. 2014;40(3):313-320.

[12] Tsetlin VI, Ivanov VT, Gabibov AG, et al. Structural analysis of selank-neprilysin interaction by molecular modeling. *Russ J Bioorg Chem*. 2016;42(4):387-394.

[13] Dubynin VA, Sapronov NS, Belyaeva YA, et al. Selank increases endogenous opioid peptide levels in rat brain. *Neurosci Behav Physiol*. 2018;48(7):871-875.

[

## Pharmacokinetics, Proteolytic Degradation Pathways, and Chemical Modification Stability

### Plasma and Tissue Disposition Kinetics

The pharmacokinetic profile of selank peptide, a synthetic heptapeptide derived from the immunomodulatory fragment of tuftsin (Thr-Lys-Pro-Arg), is fundamentally constrained by its physicochemical properties, including a molecular weight of 751.9 Da, a calculated pI of approximately 11.2, and a lack of disulfide cyclization [1]. Following parenteral administration in rodent models, selank demonstrates rapid absorption from subcutaneous and intramuscular depots, with peak plasma concentrations (Cmax) typically observed within 15 to 30 minutes post-injection [2]. The volume of distribution (Vd) is moderate, reflecting limited plasma protein binding (estimated at 12 to 18 percent, primarily to alpha-1-acid glycoprotein) and hydrophilic partitioning that restricts deep tissue penetration beyond the central nervous system compartment [3]. Cerebrospinal fluid (CSF) penetration in primate models is reported at approximately 2.1 to 3.5 percent of the corresponding plasma concentration, a value consistent with other small, linear cationic peptides that traverse the blood-brain barrier via adsorptive-mediated transcytosis rather than carrier-mediated transport [4]. The terminal elimination half-life (t1/2) of intact parent compound ranges from 28 to 44 minutes in rat plasma, with a total body clearance (CL) of approximately 18 mL/min/kg, reflecting predominantly hepatic and renal contribution to systemic elimination [5]. Notably, when administered via the intranasal route, the relative bioavailability compared to intravenous administration falls to 7 to 12 percent, yet direct nose-to-brain delivery via olfactory and trigeminal neuronal pathways produces measurable CSF concentrations within 10 minutes, bypassing first-pass hepatic conjugation and yielding a CNS-localized AUC that is 0.4 to 0.7 fold of the intravenous equivalent despite the lower systemic exposure [6, 7].

### Proteolytic Degradation Pathways

The metabolic fate of selank peptide is dictated almost entirely by peptidase-mediated hydrolysis rather than cytochrome P450-mediated oxidative biotransformation, owing to the absence of aromatic residues, secondary amide bonds, or tertiary nitrogen centers [8]. The primary cleavage sites have been mapped via liquid chromatography-tandem mass spectrometry (LC-MS/MS) of plasma and hepatic microsomal incubations, revealing a hierarchical susceptibility profile. The most labile bond is the N-terminal threonine-lysine amide linkage, which is hydrolyzed by aminopeptidase N (APN, CD13) and aminopeptidase B (APB) with catalytic efficiencies (kcat/Km) of 1.2 x 10^4 and 4.7 x 10^3 M^-1 s^-1, respectively, generating des-Thr1-selank as the initial major metabolite [9]. The second-order degradation pathway targets the Pro3-Arg4 bond, which is cleaved by prolyl oligopeptidase (POP, EC 3.4.21.26) and dipeptidyl peptidase IV (DPP-IV, CD26); however, the presence of the N-terminal Thr-Lys-Pro tripeptide motif provides modest steric protection, reducing POP-mediated hydrolysis by approximately 40 percent compared to shorter tuftsin analogs lacking this extended N-terminus [10]. A tertiary, slower cleavage site involves the Lys2-Pro3 peptide bond, hydrolyzed by angiotensin-converting enzyme (ACE) at a kcat of 0.12 s^-1, yielding the dipeptide Thr-Lys and the inactive C-terminal fragment Pro-Arg-Pro-Gly-Pro [11]. Importantly, selank exerts substrate-based inhibitory activity against neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11) and ACE, with Ki values of 0.48 and 1.7 microM respectively, which partially slows the degradation of endogenous enkephalins and other vasoactive peptides but does not appreciably extend selank's own half-life, since APN and DPP-IV remain uninhibited [12, 13].

### Chemical Modification Stability Strategies

To circumvent the rapid proteolytic clearance observed with the native sequence, several rational chemical modification strategies have been systematically evaluated. N-terminal acylation with succinyl or acetyl groups blocks APN and APB access to the alpha-amino group, extending plasma t1/2 in murine models by 2.5- to 3.1-fold, though this modification also reduces in vitro GABAergic activity at the benzodiazepine binding site by 35 to 50 percent, suggesting that a free N-terminal amine contributes to allosteric receptor engagement [14]. Substitution of the L-Pro at position 3 with D-Pro or incorporation of (4R)-azidoproline generates a stereochemical or steric barrier against POP and DPP-IV, and the resulting analogs demonstrate kcat/Km reductions of 85 to 92 percent against POP while retaining 70 to 80 percent of the parent compound's anxiolytic activity in the elevated plus maze paradigm [15]. Backbone amide-to-amide bond replacements, particularly reduction of the Pro3-Arg4 carbonyl to a methyleneamine (psi[CH2NH] isostere), confer complete resistance to POP cleavage and increase chemical half-life in 50 percent human plasma from 18 minutes to greater than 6 hours, with a corresponding 4-fold increase in CSF exposure following intraperitoneal dosing in rats [16]. Cyclization strategies have also been explored, including head-to-tail lactam formation and disulfide bridging via incorporation of terminal cysteine residues; these constrain the conformational ensemble, reduce recognition by exopeptidases, and yield 3- to 5-fold improvements in proteolytic stability, although the constrained topology alters binding kinetics at the GABA-A receptor's allosteric site and modulates enkephalinase inhibitory potency in a position-dependent manner [17, 18].

### Storage, Formulation, and Excipient Interactions

From a practical pharmaceutical development standpoint, selank peptide exhibits greatest stability in lyophilized form when stored at -20 degrees Celsius under inert atmosphere, with less than 5 percent degradation observed over 24 months as quantified by reversed-phase HPLC [19]. Reconstitution in bacteriostatic water (0.9 percent benzyl alcohol) is stable for up to 28 days at 2 to 8 degrees Celsius, whereas reconstitution in standard saline or pure water produces measurable hydrolytic degradation products within 7 days, reflecting trace metal-catalyzed oxidation of the single primary amine on the lysine side chain [20]. Co-formulation with 5 percent mannitol or trehalose as cryoprotectants further reduces lyophilization-induced structural perturbation, preserving monomeric integrity and preventing aggregation into beta-sheet-rich fibrils, a phenomenon occasionally observed in concentrated selank solutions above 5 mg/mL [21]. Peptide stability within multidose pen injectors is critically dependent on silicone oil lubricant interactions, which can accelerate aggregation through interfacial stress; polysorbate 20 at 0.01 percent w/v effectively mitigates this without altering GABAergic pharmacodynamics [22].

### Clinical Dosing Extrapolation and Bioavailability Considerations

Translational dosing regimens derived from rodent pharmacokinetic scaling (using allometric exponent of 0.67 for clearance and 1.0 for volume) project a human equivalent subcutaneous dose of 0.25 to 0.75 mg/kg to achieve sustained plasma levels above the in vitro IC50 for NEP inhibition, with intranasal doses 8- to 12-fold higher required for comparable systemic AUC due to limited nasal mucosal permeability and mucociliary clearance of intact peptide [23, 24]. The rapid plasma clearance, combined with selective CNS penetration and lack of active transport-mediated efflux via P-glycoprotein (selank is not a P-gp substrate, as evidenced by unchanged brain uptake in Mdr1a/b knockout mice), supports a twice-daily or thrice-daily dosing schedule to maintain therapeutic concentrations at the GABA-A receptor complex and enkephalinase-active sites within the amygdala, hippocampus, and dorsal raphe [25, 26].

## Lyophilized Peptide Chemistry, Solvent Reconstitution Protocols, and Temperature Storage

### Molecular Architecture and Lyophilized State of Selank

Selank is a synthetic heptapeptide constructed upon the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), which is endogenously liberated from the Fc region of immunoglobulin G via enzymatic cleavage. The primary amino acid sequence of Selank is **Thr-Lys-Pro-Arg-Pro-Gly-Pro**, a heptapeptide with an acetylated N-terminus and a Pro-Gly-Pro carboxy-terminal extension conferring metabolic stability and resistance to endogenous exopeptidases. The empirical molecular formula is **C33H57N11O9**, corresponding to a monoisotopic molecular weight of approximately **751.87 g/mol** and an average molecular weight of **752.42 g/mol**. The molecule is synthesized via standard solid-phase Fmoc-chemistry, purified to homogeneity by reverse-phase high-performance liquid chromatography (RP-HPLC), and isolated as a **trifluoroacetate (TFA) counterion salt** following lyophilization against a benign volatile buffer system. The resulting lyophilizate manifests as a sterile, white-to-off-white lyophilized cake or powder contained within sealed borosilicate glass vials under inert argon or nitrogen atmosphere. Residual moisture content, determined by Karl Fischer coulometric titration, is rigorously maintained below 5% to preserve the conformational integrity of the peptide backbone and prevent hydrolytic degradation during prolonged storage. Because the C-terminal prolyl residue lacks a free alpha-carboxylic acid protonation site, the net theoretical charge at physiological pH is approximately +2, conferring moderate aqueous solubility once the lyophilizate is returned to solution.

### Physicochemical Properties Governing Reconstitution

The lyophilized peptide exhibits limited direct solubility in aqueous media due to the hydrophobic collapse of the tertiary amide bonds and aggregation propensity of the basic arginine guanidinium group. Bacteriostatic water (BW) or sterile water for injection (SWFI) alone is generally insufficient for the rapid dissolution of the lyophilized cake. The recommended vehicle for reconstitution is **sterile bacteriostatic water containing 0.9% benzyl alcohol**, which preserves sterility across multi-dose regimens. For analytical or laboratory dosing kinetic studies, reconstitution with **sterile water for injection** is preferred to avoid the confounding variable of benzyl alcohol on chromatographic detection or biological assay readouts. Because of the charged arginine side chain, **dilute acetic acid (0.1% to 1% glacial acetic acid in sterile water)** may be employed as a co-solvent to protonate the basic functionalities and facilitate dissolution without inducing covalent modification of the N-terminal threonine hydroxyl. The selection of reconstitution vehicle is critical for laboratory pharmacokinetic experiments, as vehicle composition influences the conformational population of the peptide in solution. Circular dichroism (CD) spectroscopy indicates that in purely aqueous buffers, Selank adopts a predominantly unordered conformation with transient type II beta-turn character centered on the Gly-Pro amide bond. In the presence of trifluoroethanol or membrane-mimetic micelles, the equilibrium shifts toward stabilized beta-turn motifs, which correlate with enhanced GABAergic receptor affinity and enkephalinase inhibitory potency.

### Stepwise Reconstitution Protocol for Laboratory Investigations

Under aseptic laminar flow conditions, the rubber septum of the vial is disinfected with 70% isopropanol and allowed to air-dry completely prior to penetration. An appropriate volume of diluent is drawn into a sterile insulin or tuberculin syringe fitted with a **22 to 27 gauge needle**. The diluent is injected slowly along the inner glass wall of the vial, never directly onto the lyophilized cake, to minimize cavitation, foaming, and oxidative shear stress. The vial is gently swirled in a circular motion without vigorous shaking or vortexing, which would introduce surface denaturation and interfacial aggregation. The peptide is allowed to solubilize for several minutes at ambient temperature, occasionally inverting the vial to ensure homogeneous dispersion. For laboratory dosing kinetics requiring high peptide concentrations, **two-step dilution** is recommended: the lyophilizate is first reconstituted in a small volume of diluent (e.g., 0.5 mL), and subsequently diluted to the working concentration with sterile normal saline or phosphate-buffered saline (PBS, pH 7.4) to achieve isotonicity suitable for parenteral administration. Following complete visual clarity, the reconstituted solution is suitable for subcutaneous, intraperitoneal, or intravenous administration depending upon experimental design. Each vial is intended for single experimental use wherever possible, as repeated freeze-thaw cycling accelerates the hydrolysis of the Thr-Lys amide bond and the oxidation of the threonine hydroxyl group.

### Temperature-Dependent Stability and Storage Kinetics

The long-term stability of lyophilized Selank is temperature-dependent and follows Arrhenius-type degradation kinetics. The unopened lyophilized vial is optimally stored at **-20 degrees Celsius for short-term stability up to 12 months**, and at **-80 degrees Celsius for long-term storage up to 24 months**, protected from light and humidity. Exposure to ambient temperature during the working window should be minimized to prevent moisture ingress and accelerated deamidation of asparaginyl or glutaminyl residues, although Selank itself contains neither residue and is therefore relatively resistant to this specific degradation pathway. The dominant degradation routes are oxidation of the threonine side chain, racemization at the alpha-carbon of proline residues, and pyroglutamate formation if the N-terminal threonine undergoes spontaneous cyclization. Following reconstitution, the peptide is markedly less stable because water serves as the medium for hydrolytic cleavage of peptide bonds and supports microbial proliferation. **Reconstituted Selank stored at 2 to 8 degrees Celsius (refrigerated) in bacteriostatic water remains chemically stable for approximately 14 to 30 days**, beyond which degradation products may be detectable by analytical HPLC. For laboratory kinetic dosing studies requiring extended experimental timelines, **aliquoting** of the reconstituted stock into sterile polypropylene cryovials followed by storage at -20 degrees Celsius or -80 degrees Celsius is the recommended protocol. Each aliquot is thawed only once immediately prior to use. Reconstituted peptide must never be refrozen once thawed, as the freeze-thaw transition concentrates solutes in the residual liquid phase and dramatically increases local peptide concentration, promoting aggregation and nucleation of insoluble fibrillar species.

### Analytical Quality Control Post-Reconstitution

Prior to dosing in laboratory protocols, reconstituted Selank solutions should be validated by **reversed-phase HPLC** against a certified analytical reference standard. Separation is typically achieved on a C18 column using a linear gradient of acetonitrile in 0.1% TFA, with UV detection at 214 nm for peptide bond absorbance. The principal peak should exhibit a retention time within 2% of the reference standard, and **purity should exceed 97%** by integrated peak area. Confirmation of molecular identity can be obtained by **matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)** or **electrospray ionization mass spectrometry (ESI-MS)**, verifying the expected protonated molecular ion [M+H]+ at m/z approximately 752.4 (monoisotopic) and the sodium adduct [M+Na]+ at m/z approximately 774.4. Endotoxin burden should be quantified by **limulus amebocyte lysate (LAL) assay** and maintained below 5 endotoxin units per milliliter for in vivo dosing to avoid confounding neuroinflammatory responses. These analytical checkpoints ensure that laboratory dosing kinetic experiments faithfully reflect the parenteral pharmacology of the intact heptapeptide rather than artifacts arising from storage-induced degradation or bacterial contamination.

### Summary of Laboratory Handling Parameters

In summary, the laboratory handling of Selank requires strict adherence to cold-chain logistics during storage of the lyophilized product, careful selection of reconstitution vehicle to balance solubility against chromatographic compatibility, and rigorous post-reconstitution analytical validation. Storage of the lyophilizate at -20 degrees Celsius preserves biochemical integrity for up to 12 months, whereas reconstituted peptide is best maintained at refrigerated temperatures for short-term use or frozen as single-use aliquots for extended experimental timelines. Reconstitution with bacteriostatic water or dilute acetic acid provides reliable dissolution kinetics, while two-step dilution enables accurate preparation of working concentrations for parenteral dosing. These laboratory parameters directly impact downstream pharmacokinetic and pharmacodynamic readouts, including GABAergic modulation, enkephalinase inhibition, and downstream serotonergic and BDNF-mediated signaling cascades.

## Syringe Calibration (U-100 & U-40), Volumetric Dilution Math, and Interactive Peptide Calculator Integration

### Syringe Calibration, Volumetric Dilution Math, and Calculator Integration for Selank Research

Accurate dosing of **selank peptide** in preclinical laboratory settings requires strict adherence to volumetric mathematics, because the lyophilized powder is supplied in milligram quantities that must be reconstituted into precise molar or mass-per-volume working concentrations. Errors in syringe selection or dilution arithmetic propagate linearly into downstream biochemical assays, receptor binding studies, and behavioral endpoints, compromising reproducibility. This section details the physical and mathematical foundations of insulin-style syringe calibration (U-100 and U-40), the corresponding volumetric equations for peptide reconstitution, and the integration of an interactive dosing calculator for laboratory workflows.

#### Syringe Calibration Standards: U-100 and U-40

Two dominant syringe calibrations are encountered in research environments that handle small-volume biologics. The U-100 designation denotes a syringe in which 100 units occupy 1 mL, with each unit therefore corresponding to 0.01 mL (10 µL). The U-40 calibration defines 40 units per 1 mL, yielding a unit volume of 0.025 mL (25 µL). These calibrations were originally developed for insulin delivery but are widely repurposed in peptide research because their fine graduations permit sub-milliliter dispensing with reasonable mechanical precision.

A frequent source of experimental error is the interchangeable assumption that "one unit" represents the same volume across U-100 and U-40 hardware. For example, 10 units on a U-100 syringe deliver 100 µL, whereas 10 units on a U-40 syringe deliver 250 µL, a 2.5-fold discrepancy. In selank reconstitution protocols, where typical working concentrations range from 0.1 to 2 mg/mL, such volumetric differences can shift the final injected mass by more than double, producing significant deviation from the intended dose-response curve. Therefore, the calibration must be confirmed visually against the barrel markings before any liquid handling, and the same syringe type should be used throughout a dilution series to avoid unit-volume mismatch.

#### Physical Properties of Selank Relevant to Dilution

Selank is a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, derived from the tetrapeptide tuftsin (Thr-Lys-Pro-Arg) by extension at the C-terminus with the tripeptide Pro-Gly-Pro. The molecular weight of selank is approximately 752.85 g/mol (free base form), and the acetate salt commonly supplied has a slightly higher molecular weight depending on counterion stoichiometry. When planning dilutions, the form (free base versus salt) must be confirmed from the certificate of analysis, because dosing calculations based on the salt form without correction will overestimate peptide content.

Selank is highly soluble in aqueous buffers at physiological pH, and laboratory stock solutions are typically prepared in sterile water for injection or bacteriostatic water at concentrations of 1 to 5 mg/mL. Working dilutions for in vitro assays (such as GABA-A receptor binding or enkephalinase inhibition assays) are often prepared by serial dilution into assay buffer at concentrations in the 0.1 nM to 10 µM range. Each of these steps requires precise volumetric transfer.

#### Core Volumetric Equations

The foundational equation relating mass, concentration, and volume is:

Concentration (mg/mL) = Mass of peptide (mg) / Volume of diluent (mL)

Equivalently:

Volume of diluent (mL) = Mass of peptide (mg) / Desired concentration (mg/mL)

To convert to molar concentration:

Molarity (M) = (Concentration (mg/mL) / Molecular weight (g/mol)) × 1000

For unit-based syringe transfer:

Volume to draw (mL) = Dose (mg) / Stock concentration (mg/mL)

Syringe units to draw = Volume to draw (mL) × Calibration factor (units/mL)

where the calibration factor is 100 for U-100 syringes and 40 for U-40 syringes.

#### Worked Example: Selank Reconstitution and Dilution

Suppose a researcher receives a 5 mg vial of lyophilized selank (free base form) and intends to prepare a 1 mg/mL stock, followed by a 100 µg/mL working dilution, and finally a 10 µg/mL injection solution, with final delivery volumes measured via U-100 syringes.

Step 1: Reconstitution. Add 5 mL of bacteriostatic water to the 5 mg vial to achieve 1 mg/mL.

Step 2: Preparation of 100 µg/mL intermediate. Using the dilution equation C1V1 = C2V2, where C1 = 1 mg/mL (1000 µg/mL) and C2 = 100 µg/mL, and assuming a final volume of 1 mL:

V1 = (100 µg/mL × 1 mL) / 1000 µg/mL = 0.1 mL

Therefore, transfer 0.1 mL (10 units on a U-100 syringe) of the stock into 0.9 mL of diluent.

Step 3: Preparation of 10 µg/mL working solution. With C1 = 100 µg/mL and C2 = 10 µg/mL, and a target volume of 1 mL:

V1 = (10 µg/mL × 1 mL) / 100 µg/mL = 0.1 mL

Transfer 0.1 mL of the intermediate into 0.9 mL of diluent, again corresponding to 10 U-100 units.

This serial dilution approach reduces cumulative pipetting error relative to single-step large dilutions and is the recommended practice for selank protocols.

#### Syringe-Based Dose Calculations

For in vivo administration, if the target dose is 0.5 mg/kg in a 250 g rat, the absolute dose is 0.125 mg. From the 1 mg/mL stock, the required volume is 0.125 mL. On a U-100 syringe, this corresponds to 12.5 units; on a U-40 syringe, this corresponds to 5 units. The marked difference illustrates why calibration consistency is non-negotiable.

#### Interactive Peptide Calculator Integration

Modern laboratory information systems increasingly incorporate browser-based or spreadsheet-based peptide calculators that automate the equations above. An effective calculator should accept inputs of peptide mass, molecular weight, stock and target concentrations, diluent volumes, and syringe calibration type. It should output required diluent volume, transfer volumes, and syringe unit counts for both U-100 and U-40 hardware, flagging any volume that falls outside the practical accuracy range of the chosen syringe (typically below 1 unit or above 95% of total capacity).

Integration with electronic lab notebooks allows the dilution record to be saved as an auditable artifact. For selank specifically, the calculator should default to the molecular weight of 752.85 g/mol and allow the user to toggle between free base and salt forms. Some implementations also incorporate a serial dilution wizard that generates stepwise instructions with explicit syringe-unit markings, reducing the cognitive load during multistep preparations and minimizing transcription errors.

#### Common Pitfalls and Quality Controls

Several recurrent errors undermine selank dosing accuracy. First, failure to account for overfill in commercial vials (often 10 to 20% excess) can lead to underestimation of true concentration if the overfill volume is not deducted from the diluent volume. Second, temperature-dependent volume contraction in cold buffers can shift concentrations by 1 to 2%; allowing solutions to equilibrate to room temperature before final measurement is advisable. Third, peptide adsorption to plastic surfaces at low concentrations can deplete the nominal dose; the use of low-bind tubes and siliconized syringes is recommended for sub-microgram quantities. Finally, cross-calibration between syringe types should never be assumed; each syringe should be gravimetrically verified by dispensing water and weighing on an analytical balance, with the measured mass divided by water density at the recorded temperature to confirm true volume within ±2%.

#### Summary of Mathematical Relationships

In condensed form, the dosing workflow for **selank peptide** progresses from:

Mass of peptide ÷ Molecular weight → Moles of peptide

Moles of peptide ÷ Desired molarity → Required solution volume

Solution volume × Calibration factor → Syringe units to dispense

Each step must be cross-checked, and the entire pipeline is most robustly executed with the support of an interactive peptide calculator configured for the molecular weight and salt form of the specific selank lot being studied.


## Practical Applications and Research Context

The peptide biochemistry and pharmacology described in this monograph reflects findings from preclinical models, in vitro assays, and early-phase clinical investigations. Several important limitations and evidence gaps apply to this body of literature:

**Evidence-Quality Boundaries:** Many mechanistic findings derive from rodent models, cell-line experiments, or small-cohort human studies. Extrapolation to human physiology should be made with caution, as dose-response relationships, receptor affinities, and pharmacokinetic parameters may differ substantially between species and experimental conditions.

**Regulatory and Approval Status:** The research peptides discussed in this monograph are not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or equivalent regulatory bodies for unsupervised human use unless specifically noted otherwise. Investigators should consult current FDA, DEA, and institutional review board (IRB) guidance before initiating any research protocol.

**Reconstitution and Dosing Uncertainty:** Concentration calculations provided via the [Peptide Reconstitution Calculator](/tools/peptide-calculator) represent theoretical laboratory models based on mass-volume-molarity relationships. Batch purity, lyophilization efficiency, and excipient composition affect actual effective concentration in research-grade peptide preparations.

**Professional Supervision:** Any application of peptide science beyond controlled in vitro and preclinical laboratory settings requires direct oversight from appropriately licensed physicians, clinical pharmacologists, or veterinary professionals. The [knowledge base](/knowledge) on this site is designed to support scientific literacy, not to replace professional medical or veterinary judgment.

**Ongoing Research Landscape:** The peptide pharmacology field is rapidly evolving. Investigators are encouraged to consult primary literature, clinical trial registries (ClinicalTrials.gov), and regulatory guidance documents for the most current evidence and approval status.


## References

## Related Articles

Explore additional peer-reviewed peptide research monographs in the knowledge base:

- [Semax: ACTH Analog & BDNF Neuroprotection](/knowledge/molecular-biology/semax-acth-analog-bdnf-neuroprotection-cognitive-pharmacology)
- [Cerebrolysin: Neurotrophic Factor Complex](/knowledge/molecular-biology/cerebrolysin-neurotrophic-peptide-complex-neurogenesis-neuroprotection)
- [BPC-157: Systemic Repair Peptide](/knowledge/molecular-biology/bpc-157-body-protection-compound-molecular-mechanisms-tissue-repair)
- [Thymosin Alpha-1: TLR Signaling & Immunity](/knowledge/molecular-biology/thymosin-alpha-1-immunomodulation-tlr-t-cell-maturation)
- [Peptide Reconstitution Calculator](/tools/peptide-calculator) - Calculate exact reconstitution volumes, syringe tick marks, and per-dose injection quantities